Quadrant Capital Group LLC Acquires 145,259 Shares of Dr. Reddy’s Laboratories Ltd $RDY

Quadrant Capital Group LLC boosted its holdings in Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 54.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 411,374 shares of the company’s stock after purchasing an additional 145,259 shares during the period. Quadrant Capital Group LLC’s holdings in Dr. Reddy’s Laboratories were worth $5,751,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Atria Investments Inc raised its stake in shares of Dr. Reddy’s Laboratories by 206.5% during the 2nd quarter. Atria Investments Inc now owns 32,733 shares of the company’s stock worth $492,000 after purchasing an additional 22,052 shares during the period. Savant Capital LLC grew its position in Dr. Reddy’s Laboratories by 131.0% during the second quarter. Savant Capital LLC now owns 27,670 shares of the company’s stock valued at $416,000 after buying an additional 15,691 shares during the period. Fox Run Management L.L.C. increased its holdings in Dr. Reddy’s Laboratories by 229.6% during the second quarter. Fox Run Management L.L.C. now owns 35,656 shares of the company’s stock worth $536,000 after buying an additional 24,839 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in Dr. Reddy’s Laboratories during the second quarter worth about $2,193,000. Finally, Acadian Asset Management LLC raised its position in Dr. Reddy’s Laboratories by 43.8% in the second quarter. Acadian Asset Management LLC now owns 2,116,358 shares of the company’s stock worth $31,798,000 after acquiring an additional 644,835 shares during the period. Institutional investors own 3.85% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Dr. Reddy’s Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, February 13th. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $16.90.

Dr. Reddy’s Laboratories Stock Performance

NYSE:RDY opened at $14.49 on Wednesday. The company has a market capitalization of $12.09 billion, a P/E ratio of 18.81, a P/E/G ratio of 13.07 and a beta of 0.34. The business has a fifty day simple moving average of $13.91 and a two-hundred day simple moving average of $14.06. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.88 and a quick ratio of 1.38. Dr. Reddy’s Laboratories Ltd has a 1 year low of $12.26 and a 1 year high of $16.17.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Wednesday, January 21st. The company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. The firm had revenue of $969.81 million for the quarter, compared to analysts’ expectations of $963.84 million. Dr. Reddy’s Laboratories had a return on equity of 15.89% and a net margin of 16.41%. On average, analysts expect that Dr. Reddy’s Laboratories Ltd will post 0.8 earnings per share for the current year.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.